Integrating cell-type-specific gene expression and genome-wide associations identifies risk genes for schizophrenia.

Mol PsychiatryMay 9, 2026 (epub)
Clinical ResearchPsychiatryOpen access

Wenqi Lou, Xinglun Dang, Xiong-Jian Luo

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis investigated the causal relationships between cell-type-specific gene expression and schizophrenia (SCZ) using expression quantitative trait loci (eQTL) data. The study identified 148 significant genes in excitatory neurons and 206 genes overall whose expression levels are causally associated with SCZ. The findings highlight the importance of cell-type specificity in understanding SCZ risk.

Key findings

  • Identified 148 significant genes in excitatory neurons associated with SCZ.
  • Found 206 genes overall whose expression levels are causally linked to SCZ.
  • Prioritized MAU2 and PPP1R13B as plausible causal genes for SCZ.
  • Conducted drug target analysis to evaluate therapeutic potential of identified genes.

Why it matters

Understanding the specific genes associated with schizophrenia can enhance the knowledge of its biological underpinnings and may lead to the development of targeted therapeutic strategies.

Source

PubMed · PMID 42106519Free full text on PubMed Central

Published in Mol Psychiatry. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.